BIIB
Undervalued by 25.2% based on the discounted cash flow analysis.
Market cap | $33.49 Billion |
---|---|
Enterprise Value | $38.96 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $8.0 |
Beta | 0.0 |
Outstanding Shares | 145,596,895 |
Avg 30 Day Volume | 1,349,081 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 28.71 |
---|---|
PEG | 2024.84 |
Price to Sales | 3.49 |
Price to Book Ratio | 2.22 |
Enterprise Value to Revenue | 4.03 |
Enterprise Value to EBIT | 20.68 |
Enterprise Value to Net Income | 33 |
Total Debt to Enterprise | 0.17 |
Debt to Equity | 0.43 |
No data
No data
At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...